Becton, Dickinson and Company (BD) has signed a co-exclusive commercial agreement with Magnolia Medical Technologies to help reduce blood culture contamination and improve testing accuracy in US hospitals.
Under the deal terms, both companies will jointly sell and market Magnolia Medical’s Steripath and Steripath Micro Initial Specimen Diversion Device platforms.
BD stated that the two platforms would complement its specimen collection portfolio, which includes the BD Vacutainer push button and BD Vacutainer UltraTouch blood collection sets.
Steripath is claimed to be the only device platform, which has received 510(k) clearance from FDA.
It has been specifically designed to reduce blood culture contamination for sepsis testing accuracy.
BD integrated diagnostic solutions president Brooke Story said: “Sepsis is the number one cause of death, readmissions and costs in hospitals today. It’s estimated that up to 56% of positive blood cultures can be contaminated during collection.
“Reducing blood culture contamination can help improve testing accuracy and ultimately improve clinical outcomes and may lessen the threat of antibiotic resistance by giving health care practitioners more specific, reliable results.”
The Steripath Initial Specimen Diversion Devices are developed for diverting and sequestering the first 1.5ml to 2ml of contaminated blood from the sample, and later, the blood will be collected for blood cultures.
BD noted that the Steripath platform offers the only all-in-one devices, which are clinically proven to meet the Clinical and Laboratory Standards Institute’s (CLSI) 1% blood culture contamination aim, as well as the new guidelines of the US Centers for Disease Control and Prevention (CDC).
Additionally, the device has been adopted by several hospitals and healthcare systems in the US to address the blood culture contamination problem.
Blood culture contamination may lead to sepsis misdiagnosis that will result in prolonged, unnecessary, and harmful antibiotic treatment, which extends the length of hospital stay and false-positive CLABSIs.
Magnolia Medical CEO Greg Bullington said: “By offering a combined innovative technology solution with the Steripath Initial Specimen Diversion Device platform and BD Vacutainer push-button and BD Vacutainer UltraTouch blood collection sets, we are aligning our shared commitment to improve patient outcomes, help hospitals achieve their quality goals, and reduce unnecessary hospital costs.”